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Introduction
Protease-activated receptor (PAR)-1 is a G-proteincoupled receptor belonging to a family of receptors whose defining feature is irreversible proteolytic activation. Proteolytic cleavage exposes a tethered ligand of the N-terminal extracellular domain, leading to intracellular signaling. Thrombin-mediated PAR-1 cleavage is a critical mechanism of platelet activation in humans [1] , but PAR-1 is not expressed by murine platelets [2] . PAR-1 is expressed by multiple other cell types in both mice and humans [3] , and PAR-1 functions have been linked to proliferation, survival, cytokine/growth factor secretion, and motility [3] . PAR-1 can be activated by several proteases in addition to thrombin, including activated protein C, matrix metalloproteases, kallikreins, plasmin, and the tissue factor (TF)-activated factor VII-activated FX complex [4] . The tethered ligand that is exposed following proteolytic cleavage of PAR-1 varies with the activating protease, leading to different or opposing cell signaling pathways [5] [6] [7] .
Consistent with the fact that PAR-1 is widely expressed and coupled to numerous cellular processes, studies in mice have shown that PAR-1 plays a major role in numerous disease processes [8] . Several experimental studies have led to a widely held view that PAR-1 activation drives cancer progression, and PAR-1 activation has been proposed as one of the mechanisms coupling thrombinmediated proteolysis to cancer progression [8] . Although many of the available data supporting this conclusion are based on in vitro analyses [9] [10] [11] [12] [13] [14] , there are ample in vivo analyses based on either specific PAR-1 inhibitors or genetic manipulation of PAR-1 in tumor cells or stromal cells [15] [16] [17] [18] [19] [20] [21] . However, the majority of the in vivo data regarding the role of PAR-1 in malignancy are based on analyses of fully transformed tumor cells. Analyses of in situ tumor progression in a murine breast cancer model showed no apparent role for PAR-1, but analyses of other spontaneous tumor models are lacking [22] .
To define the role of PAR-1 in tumor progression in the context of malignancies developing in situ, we studied PAR-1-deficient mice in two spontaneously developing murine tumor models: Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice, and mice carrying the adenomatous polyposis coli multiple intestinal neoplasia allele (Apc min/+ ), which spontaneously develop intestinal adenomas. Surprisingly, the genetic elimination of PAR-1 resulted in more aggressive tumor progression in both experimental settings, indicating that PAR-1 can function as an inhibitor of tumor progression in some contexts.
Materials and methods

Murine tumor models and statistical analysis
All mice were backcrossed for at least eight generations onto a C57Bl/6 background. Female mice carrying the TRAMP transgene [23] were interbred with PAR-1-deficient mice (F2r À/À ) [24] , hereafter referred to as PAR-1 [25] were interbred with PAR-1 À/À mice to generate APC Min/+ mice with and without PAR-1 expression. Intestinal tissue was harvested from male and female mice at 12 weeks of age. All mice used in these studies were generated in house and co-housed throughout the study. The Cincinnati Children's Hospital Research Foundation Institutional Animal Care and Use Committee approved all animal studies. Statistical analyses were performed with GRAPHPAD PRISM. Comparisons of continuous variables between genotypes were performed with a Mann-Whitney U-test. Nominal variables were compared by use of Fisher's exact test.
Histology and immunohistochemistry
Hematoxylin and eosin (H&E) staining (5-lm sections) and immunohistochemistry were performed on formalinfixed paraffin-embedded tissue, and imaging was performed with a Nikon Ni-E microscope (Minato, Tokyo, Japan). For immunohistochemistry, antigen retrieval was achieved by treating deparaffinized tissue sections in citrate buffer heated with a pressure cooker. Sections were permeabilized with 0.3% Triton X-100 in phosphate-buffered saline (PBS), and blocked with 3% goat serum in PBS. Synaptophysin (SYP) staining was performed with a mAb (H-8; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1 : 25 in a diluent prepared from the mouse-on-mouse kit (M.O.M.; Vector Laboratories, Burlingame, CA, USA). M.O.M. antigen blocking and application of the biotinylated anti-mouse secondary antibody were performed according to the manufacturer's specifications. Secondary antibody was detected with the Vector Red alkaline phosphatase kit (Vector Laboratories). Ki67-stained (1 : 100 dilution; Neomarkers, Fremont, CA, USA; #RB1510PO) and CC3-stained (1 : 100 dilution; Cell Signaling, Danvers, MA, USA; #9661s) areas were measured by morphometric analysis with the Nikon NIS-ELEMENTS program (Version 4.5) by a blinded observer.
mRNA expression analyses
Gene expression was measured in RNA isolated from prostate tissue with Trizol, and cDNA was prepared with a High Capacity RNA-to-cDNA kit (Applied Biosystems, Waltham, MA, USA). Real-time PCR analyses of SYP were performed by use of the Taqman method with probe/primer sets (Mouse Syp, Mm00436850_m1; Mouse B2 m, Mm00437762_m1; Applied Biosystems). The SV40 Large T Antigen probe/primer was a customized preparation from Applied Biosystems. Expression analyses of the genes listed in Table S1 were performed with PowerUp SYBR Green PCR Master Mix (#A25776; Thermofisher, Waltham, MA, USA) according to the manufacturer's instructions.
See Data S1 for details regarding in vitro analyses.
Results
PAR-1 deficiency enhances prostate tumor progression and promotes the formation of neuroendocrine (NE) tumors in TRAMP mice
To define the role of PAR-1 in the setting of a spontaneously occurring prostate tumor developing in situ, PAR-1 À/À mice were interbred with TRAMP mice expressing the SV40 Large T antigen under control of the prostate epithelial-specific probasin promoter [23] . (Fig. 1A) . Analysis of H&E-stained sections from all UGTs harvested at 30 weeks of age revealed that the majority of prostate tumors in PAR-1 +/+ mice were composed of highly transformed cells with an epithelial appearance (Fig. 1B) . Although the prostatic glandular structure in these mice was clearly dysmorphic, the glandular nature was still evident. The largest tumors harvested from TRAMP + /PAR-1 +/+ mice showed a more aggressive and invasive phenotype, consisting of sheets of highly transformed malignant cells without any visible glandular structure, consistent with a previously described NE phenotype (Fig. 1B) , which occurs in 10-20% of C57BL/6-derived TRAMP mice [26] . NE morphology was also readily evident in the very large tumors (> 4 g) harvested from PAR-1 À/À mice, suggesting that loss of PAR-1 promotes the development of this more aggressive phenotype (Fig. 1B) .
To specifically determine whether the genotype-dependent differences in the number of large tumors was attributable to differences in NE differentiation, we tested for NE transformation with the established NE marker SYP. Sections stained for H&E and SYP were evaluated by a blinded investigator. Consistent with initial mice were similar in size (Fig. 2C ). Although the relative difference in the frequency of NE tumors was a major contributor to the overall genotype-dependent difference in tumor mass, it is notable that genotype-dependent comparisons of epithelial tumors revealed that PAR-1 deletion resulted in increased tumor size even in the absence of NE differentiation (Fig. 2C ). This suggests that loss of PAR-1 might promote prostate tumor growth through mechanism(s) independent of NE differentiation.
PAR-1 promotes apoptosis in transformed prostate epithelia
To define the role of PAR-1 in early TRAMP tumor progression, we investigated prostate tumor development at 12 weeks of age, a time point well before the NE switch.
Similarly to what was observed in 30-week-old mice, UGTs harvested from PAR-1 À/À mice tended to be smaller than those harvested from control mice in the absence of the TRAMP transgene, but this difference did not reach statistical significance. In contrast to 30-week-old mice, UGTs harvested from PAR-1 +/+ and PAR-1 mice, whereas no difference was discernible between UGTs from TRAMP + and TRAMP À /PAR-1 +/+ mice (Fig. 3A) . These findings imply that tumor growth rates are accelerated by systemic loss of PAR-1 even at this early stage of tumor progression. Measurement of SV40-T mRNA from UGTs harvested at this time point revealed no PAR-1-dependent differences (data not shown), indicating that any PAR-1-dependent differences observed in TRAMP mice were not simply attributable to genotype-dependent differences in expression of the TRAMP transgene.
Histological analyses of prostate tissue harvested from 12-week-old TRAMP + mice demonstrated that all of the mice had clear signs of prostatic intraepithelial neoplasia (PIN) regardless of PAR-1 genotype. On the basis of H&E analysis, there were no obvious histological differences between cohorts (Fig. 3B ). The prostate epithelia from TRAMP + mice consisted of irregular, atypicalappearing epithelial cells with large nuclei, frequent nucleoli, and loss of polarity. Although there was evidence of crowding and a multilayer appearance, the abnormal epithelia retained a glandular morphology, and remained confined to the acinus without evidence of invasion. On the basis of SYP staining, none of the prostates harvested at this early time point had any histological evidence of NE differentiation, regardless of PAR-1 genotype (data not shown). Consistent with this, SYP mRNA expression was similar between UGTs harvested from PAR-1 +/+ and PAR-1 À/À mice carrying the TRAMP transgene (Fig. 3C) .
To determine the impact of PAR-1 on the proliferative capacity of prostate epithelia in TRAMP + mice at this early time point, prostate sections from PAR-1 +/+ and PAR-1 À/À mice were stained for the proliferative marker Ki67. As expected, Ki67 + cells were relatively common in areas of PIN, and rare in areas of nontransformed prostate or TRAMP À prostates, regardless of genotype. When calculated as a percentage of Ki67 + nuclei relative to total nuclei in areas of prostate epithelium, the frequency of proliferative cells was similar between PAR-1 genotypes (Fig. 3B,D) . We next analyzed the effect of PAR-1 deletion on the survival of transformed prostate epithelia by immunohistochemically staining for the apoptosis marker cleaved caspase 3 (CC3). Genetic elimination of PAR-1 resulted in significantly less cell death, as shown by decreased CC3 staining relative to control mice (Fig. 3B,E) . Only rare CC3 staining was observed in non-transformed prostate epithelia from TRAMP À mice, regardless of PAR-1 genotype (data not shown).
Activated protein C-mediated PAR-1 activation promotes TRAMP tumor cell apoptosis
In order to define the tumor cell-intrinsic potential of PAR-1 activation to promote apoptosis in TRAMP prostate tumor cells, we exposed well-established TRAMP-C1 cells [27] to peptide mimetics of activated protein C-mediated (TR47) or thrombin-mediated (TR42) PAR-1 activation [7] and measured CC3 activity. Analyses performed 30 min and 24 h after TR47 exposure revealed that activated protein C-mediated PAR-1 activation induced apoptosis in TRAMP-C1 cells (Fig. 4A ), whereas TR42 exposure had no effect on CC3 activity. We also evaluated the potential of these peptide mimetics to promote phosphorylation of extracellular signal-regulated kinase (ERK) 1/2 in TRAMP-derived cells. Here, TR42 exposure resulted in a significant increase in ERK phosphorylation relative to TR47 (Fig. 4B) . Increased in vitro PAR-1-mediated apoptosis is consistent with our in vivo findings of increased apoptosis in PAR-1-sufficient prostate tumors. Collectively, these data support the working concept that thrombin and activated protein C have opposing effects on prostate tumor cells, and that activated protein C-mediated activation of PAR-1 expressed by transformed prostate epithelial cells could promote apoptosis, thereby limiting tumor progression.
Previous studies have shown that PAR-2 promotes tumor progression [22, 28] , and that PAR-1 and PAR-2 play cooperative roles in some contexts [29, 30] . In order to determine the impact of PAR-1 deletion on the expression of other PARs, as well as key cellular components of the hemostatic system, we compared the expression of PAR-2, PAR-3, PAR-4, TF, thrombomodulin (THBD) and endothelial protein C receptor (EPCR) in prostates harvested from 12-week-old TRAMP mice with and without PAR-1 deletion. Prostates harvested from PAR-1 À/À TRAMP mice showed diminished expression of PAR-2 and PAR-3 relative to PAR-1 +/+ mice (Fig. S1) . No genotype-dependent differences were observed in the expression of PAR-4, TF, THBD, or EPCR (Fig. S1) . Analyses of PAR expression in non-transformed (TRAMP-negative) prostate tissue revealed similar diminutions in PAR-2 and PAR-3 in PAR-1 À/À mice (Fig. S1 ), indicating that these differences were not related to the TRAMP transgene or downstream transformation events.
PAR-1 deficiency enhances spontaneous intestinal adenoma formation
To determine the role of PAR-1 in an experimental setting of in situ tumorigenesis without NE differentiation, PAR-1 À/À mice were interbred with mice heterozygous for a tumor suppressor mutation in the adenomatous polyposis coli gene. These APC Min/+ mice develop multiple intestinal adenomas throughout the intestinal tract, with 100% penetrance. PAR-1 +/+ and PAR-1 À/À mice carrying the Apc min/+ allele were harvested at 12 weeks of age, which is a time point at which multiple adenomas are expected. The entire small intestine and large intestine were harvested, prepared as Swiss rolls, and evaluated histologically for evidence of adenoma formation.
As expected, mice carrying the Apc min/+ allele developed multiple adenomas, primarily in the small intestine. Adenomas generally consisted of nodular thickening of the mucosa characterized by elongated glands, nuclear pleomorphism, loss of polarity, and loss of cellular orientation, with some glands being characterized by epithelial cell piling (Fig. 5A) . Adenomas harvested from APC Min/+ /PAR-1 À/À mice were similar in overall morphology to those harvested from PAR-1-expressing mice (Fig. 5A ). Although they were qualitatively similar, loss of PAR-1 led to an approximately three-fold increase in the number of gastrointestinal (GI) adenomas (Fig. 5B) . Data stratified by GI tract regions (jejunem, ileum, and colon) showed that loss of PAR-1 did not affect the relative locations of developing adenomas (Fig. 5C ). Consistent with previous reports [25] , the majority of adenomas formed in the ileum, followed by the jejunum, and only a small fraction were evident in the colon, regardless of PAR-1 genotype. Although the overall architecture of adenomas was similar between genotypes, adenomas harvested from PAR-1 À/À mice were generally larger than those harvested from PAR-1 +/+ mice. This was confirmed by morphometric analyses of adenoma surface area visible in histological cross-sections. Paralleling the observations in prostate tumors, adenomas harvested from PAR-1 À/À mice were approximately two-fold larger than those harvested from control mice (Fig. 5A,D) . The non-adenomatous intestinal tissue from these mice appeared healthy and was indistinguishable between genotypes (Fig. 5E ). Note that approximately equal numbers of male and female APC Min/+ mice were used in these studies. Separate analyses revealed that the PAR-1 dependence on adenoma number and size was similar in males and females, and therefore not dependent on sex (data not shown).
PAR-1 promotes apoptosis of transformed epithelia in APC
Min/+ mice
In light of the observation that PAR-1 induces apoptosis but not cellular proliferation in transformed prostate epithelium, we next tested the proliferative/cell death indices of adenomatous intestinal epithelium from APC Min/+ mice. Staining for the nuclear proliferation marker Ki67 revealed that the overwhelming majority of intestinal epithelial cells in adenomatous tissue stained strongly positive for Ki67, regardless of PAR-1 genotype (Fig. 6A) . Proliferation in non-adenomatous intestinal epithelial tissue was limited to the proximal third of the intestinal crypts, and was also similar between PAR-1 genotypes (Fig. 6A) .
In order to determine whether PAR-1 promotes the apoptosis of transformed intestinal epithelia, intestinal tissue was tested for the presence of the apoptosis marker CC3 in transformed and healthy-appearing tissue. Paralleling observations in TRAMP mice, the genetic elimination of PAR-1 resulted in a significant decrease in the number of CC3-positive staining cells in intestinal adenomas. As a function of apoptotic CC3-positive cells per unit area, adenomas from APC Min/+ /PAR-1 À/À mice showed~35% fewer apoptotic foci than adenomas from APC Min/+ /PAR-1 +/+ mice (Fig. 6A,B) . Also paralleling results in TRAMP mice, the genotype-dependent difference in CC3 foci was limited to transformed epithelia. In healthy-appearing non-tumorous epithelial tissue, the frequency of CC3-positive cells was not different between PAR-1 genotypes (data not shown).
Discussion
These studies establish that PAR-1 functions can limit tumor progression in two distinct settings in vivo: one driven by oncogene expression (TRAMP mice), and one driven by the loss of a tumor suppressor gene (APC Min/+ mice). These studies show that one mechanism by which PAR-1 appears to limit tumor progression is by promoting the apoptosis of transformed cells at a relatively early stage in tumor development, thereby limiting tumor growth potential. Although the mechanistic details remain to be fully resolved, these studies reveal a previously unrecognized function of PAR-1 in suppressing tumor growth.
The findings presented here are surprising in that the preponderance of the literature suggests that PAR-1 promotes tumor progression. This conclusion is based on in vitro analyses, which may be limited by factors such as the lack of tumor-stromal cell interaction [9] [10] [11] [12] [13] [14] , as well as multiple detailed in vivo analyses based on highly specific PAR-1 inhibitors [18] , or genetic manipulation of PAR-1 in tumor cells or stromal cells [15] [16] [17] [18] [19] [20] [21] 31, 32] . Further complicating the picture, analyses of a murine model of spontaneously developing breast carcinoma demonstrated no impact of PAR-1 deletion on tumor progression [22] . Clearly, PAR-1 plays a context-dependent role in tumor pathogenesis. Notably, previous in vivo studies in which PAR-1 was shown to promote tumor progression utilized transplantable, fully transformed xenograft and congenic tumor cell lines, whereas the current study was based on spontaneous, in situ tumor development. It is conceivable that PAR-1 plays very different roles in earlier stages of tumorigenesis than in later stages, when tumors are fully transformed. Future studies focused on targeting PAR-1 at different time points in tumor development could better define its role at each stage of cancer progression. It is also conceivable that PAR-1 has a distinctly specific role (or no role whatsoever) in cancer progression according to the tumor type. The studies presented here represent the first analyses of PAR-1 in prostate and intestinal tumorigenesis. It is entirely conceivable that analyses of PAR-1 in the progression of other tumor types may yield very different results.
A major finding regarding the role of PAR-1 in TRAMP mice was more frequent NE prostate tumor differentiation in PAR-1 À/À mice analyzed at later stages of cancer progression. NE differentiation is a rare occurrence in human prostate cancer, but is clinically relevant, as it is associated with a dismal prognosis [33] . Determining whether PAR-1 plays a role in NE differentiation in human prostate cancer will require further study. However, analyses at an early stage of disease, prior to NE differentiation, showed that loss of PAR-1 also diminished apoptosis in transformed prostate epithelia. This finding was recapitulated in earlystage intestinal adenomas from APC Min/+ mice, i.e. an experimental context without NE differentiation. One straightforward explanation for the relative increase in NE tumors in PAR-1-deficient TRAMP mice is that PAR-1 deletion increases the chance of individual tumor cell survival, thus leading to a greater likelihood of an NE switch. The data presented here also suggest that activation of tumor cell-associated PAR-1 by activated protein C rather than by thrombin promotes apoptosis in TRAMPderived tumor cells. However, the extracellular region of PAR-1 can be cleaved at various amino acid residues by upwards of 12 different enzymes [34] , making firm identification of the PAR-1 activator in this context impossible. Activated protein C-mediated PAR-1 signaling is generally considered to have cytoprotective effects on endothelial and other cells [7, 35] , so increases in apoptosis in the presence of the activated protein C-like PAR-1 signaling mimetic TR47 is unexpected. The PAR-1 interactome of cancer cells is likely to differ from that of endothelial cells. This illustrates that different cells, and especially cancer cells, may have adapted responses to natural stimuli, but the PAR-1 interactomes of different cells remain poorly defined. Moreover, the precise role of activated protein C-mediated versus thrombin-mediated PAR-1 activation in these experimental contexts was not evaluated in vivo. The recent generation of mice carrying specific mutations in PAR-1 that bias signaling towards a particular protease [36] could be invaluable in better resolving the mechanistic puzzle of which activator drives specific individual phenotypes. Finally, the potential of PAR-1 activation by proteases other than thrombin and activated protein C to promote apoptosis cannot be discounted [37] .
Further complicating our understanding of PAR-1 biology is the fact that this receptor is expressed on multiple cell types in the tumor microenvironment in addition to tumor cells, including macrophages, endothelial cells, and fibroblasts [3] . The current studies point to at least one tumor cell-intrinsic mechanism involving PAR-1-driven apoptosis, but cannot exclude the possibility of tumor cell-extrinsic PAR-1-dependent mechanisms. The generation of mice with cell type-specific PAR-1 deletion would be useful for determining whether tumor cell-extrinsic mechanisms are at play in these experimental settings. It is also worth noting that several recent studies have shown that PAR-1 and PAR-2 play cooperative signaling roles in some contexts [29, 30] , and PAR-2 has been shown to promote tumor progression [22, 28] . It remains to be determined whether alterations in PAR-2 signaling resulting from loss of PAR-1-PAR-2 heterodimers play any role in the phenotype observed in the studies presented here. However, it is notable that PAR-2 expression was significantly diminished in the prostates of PAR-1 À/À mice, regardless of the presence of the TRAMP transgene. The relative loss of PAR-2 expression in PAR-1 À/À murine prostates makes it seem less likely that mechanisms related to PAR-2-driven tumor growth play a significant role here.
In summary, these data reveal a previously underrecognized role of PAR-1 in impeding tumor progression in the context of two independent murine models of cancer. Whether PAR-1 ever plays a similar role in human malignancies remains to be determined. Previous studies showed a correlation between increased PAR-1 expression and poor prognosis in human prostate cancer [38] , suggesting that PAR-1 drives prostate cancer progression. However. it is conceivable that PAR-1 expressed by some cellular compartments promotes cancer progression, whereas PAR-1 in other compartments limits it. In this regard, it is notable that the preponderance of PAR-1 upregulation in human prostate cancer appears to occur in the endothelial compartment [39] . Complete elimination of PAR-1 would reflect the summation of all PAR-1 activities in all cell types. Therefore, the current study may represent a cautionary note on the long-term use of PAR-1 inhibitors. The clinical use of PAR-1 inhibitors to prevent thromboembolic complications is relatively recent [40] , making it impossible to know whether long-term PAR-1 inhibition has any impact, positive or negative, on tumorigenesis in humans. Several studies have shown a correlation between long-term anticoagulation and a decreased incidence of multiple types of cancer, including prostate cancer [41] [42] [43] , suggesting that thrombin may play a role in early events that are important in tumorigenesis. Indeed, this conclusion is supported by numerous studies in animal models [44] , including studies showing that thrombin inhibition significantly limits prostate tumor progression in TRAMP mice [45] . However, thrombin has > 12 recognized substrates, and the data presented here suggest that thrombin does not promote tumor progression in TRAMP mice via a mechanism coupled to PAR-1 activation. Further study is critically needed to better understand the mechanisms coupling PAR-1 functions to cancer progression, and to determine whether there are contexts in which long-term PAR-1 inhibition could pose a cancer risk. Addendum J. S. Palumbo designed and supervised the study, acquired and analyzed data, and revised the manuscript. G. N. Adams assisted in study design, acquired and analyzed data, and wrote the manuscript. K. A. Steinbrecher acquired and analyzed data, assisted with study design and interpretation of data, and reviewed and edited the manuscript. M. J. Flick and D. P. Witte assisted with study design and interpretation of data, and reviewed and edited the manuscript. L. O. Mosnier provided critical reagents, and reviewed and edited the manuscript. B. K. Sharma, M. Frederick, L. Rosenfeldt, and E Harmel-Laws generated data and offered critical technical and material support.
